Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 October 2019 | Story Anneri Meintjes | Photo Charl Devenish
Anneri Meintjes
Anneri Meintjes from the Centre for Teaching and Learning at the UFS.

The #FeesMustFall student-led movement started in 2015 to protest against increasing student fees and to call for increased government funding of universities. At the end of 2016, the protests led to mass disruption of academic activities in higher-education institutions countrywide. Some universities, including the University of the Free State (UFS), suspended academic activities for extended periods which necessitated online and blended learning approaches (the combination of face-to-face and online learning) to complete the academic year. In most cases, these methods were unplanned and unstructured, and knowledge gaps in good blended learning practice were identified.

The Carnegie Corporation of New York funded a two-year research project in collaboration with the University of Pretoria, UFS, University of Cape Town and University of Johannesburg to investigate the use of blended learning at the end of 2016, during the campus disruptions, as well as how these respective institutions used blended learning in 2017.

The prohibitive cost of data in South Africa means few of our students have access to the internet off-campus. The most recent data on UFS student digital identity shows that only 21% have consistent, reliable access to the internet at home. This is a challenge not only for the UFS but for all universities in the country.

“For technology to be used in a way that contributes to learning and teaching, we needed to investigate what works well and what does not, considering our contextual challenges” says Anneri Meintjes from the Centre for Teaching and Learning, who was the principal researcher for the UFS on this project. In the first phase of the research, she wrote a case study on the UFS’ approach to blended learning during and after the protests in 2016. The findings of this phase of the research were presented at a national convening of higher-education institutions across South Africa.

In the second phase of the research, the four participating universities produced open educational resources on good, blended learning practice to share with universities countrywide. The UFS was responsible for the development of online assessment resources and general best-practice guidelines for the use of blended learning. Anneri says: “While we had laid solid foundations for the effective use of online assessment at the UFS prior to 2016 through the investment in online assessment software and staff development in online assessment design, we learnt many valuable lessons during that time. It provided momentum for the establishment of formal online assessment procedures and refinement of best-practice guidelines. This research project gave us an opportunity to share our work on a national platform.” The number of lecturers that use online assessment in their modules has grown considerably at the UFS since 2016. In 2016, 211 online assessments were completed on Questionmark (UFS online assessment programme) and in 2018, this number had grown to 743. Institutional Blackboard use data shows that at least one online assessment tool is used in 47% of all modules on Blackboard.

Resources developed by the other participating institutions include a self-evaluation app that academics can use to reflect on their existing blended learning practices, and an online utility that assists lectures and course designers to plan blended learning modules.

Anneri also coordinated the development of the national website, which was launched at the Flexible Futures conference hosted by the University of Pretoria on 9-10 September 2019. The website and resources were praised at the conference for being a timely response to a critical need in the higher education community in South Africa.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept